Clinical Trials Logo
  1. Home
  2. Cachexia
  3. NCT03606317
  4. Details
NCT03606317 Clinical Trial

Retrospective Review of Cachexia in Lung and Gastrointestinal Cancer Patients

Cachexia Clinical Trial

Official title:
Retrospective Review of Cachexia in Lung and Gastrointestinal Cancer Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT03606317
Other study ID # STU 092013-028
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date November 26, 2013
Est. completion date March 18, 2025

Study information
Verified date April 2024
Source University of Texas Southwestern Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective is to perform a retrospective chart review of patients with cachexia related to cancer in patients treated at UT Southwestern Medical Center and Parkland Hospital to evaluate the prognosis and practice patterns in management of cachexia and associated symptoms.

Description:

The definition of cachexia has not been fully elucidated, but there are many similar parameters and guidelines associated with identifying patients with cachexia. Cachexia is a clinical diagnosis associated with weight loss, decreased muscle mass (sarcopenia), decreased strength, fatigue, and an increased inflammatory state. Patients with cachexia have a poorer prognosis than patients who have maintained their weight. Also, patients who have lost weight prior to initiating definitive therapy have worse side effects from subsequent therapy. This study involves no treatment or invasive procedures. The chart review will attempt to characterize lung and gastrointestinal cancer related cachexia in the setting of a palliative care clinic including both primary treatment and treatment at the time of recurrence. Interventions in cachectic patients for weight control including nutritional support and supplements, pain control, anti-inflammatory medications, and appetite stimulants will be tracked along with clinical markers including weight and laboratory values.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 20000
Est. completion date March 18, 2025
Est. primary completion date March 18, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: Medical charts representing patients with a diagnosis of lung or gastrointestinal cancer with a tissue diagnosis from 1/1/2005 and onward treated at UT Southwestern or Parkland. Exclusion Criteria: There will be no absolute exclusion criteria as long as the inclusion criteria have been met.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (2)
Lead Sponsor Collaborator
University of Texas Southwestern Medical Center Parkland Health and Hospital System

Outcome
Type Measure Description Time frame Safety issue
Primary Prognosis and practice patterns in the management of cachexia and its associated symptoms. This study involves no treatment or invasive procedures. The chart review will attempt to characterize lung and gastrointestinal cancer related cachexia including both primary treatment and treatment at the time of recurrence. Interventions in cachectic patients for weight control including nutritional support and supplements, pain control, anti-inflammatory medications, and appetite stimulants will be tracked along with clinical markers, including weight and laboratory values. 10 years
See also
  Status Clinical Trial Phase
Recruiting NCT05603585 - Optimal Protein Supplementation and Early Exercise In Mechanically Ventilated Patients N/A
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Completed NCT01696604 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT02567773 - Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078 Phase 1
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2
Active, not recruiting NCT00710632 - Screening to Predict Weight Loss in Patients With Cancer N/A
Completed NCT00031785 - Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer Phase 3
Withdrawn NCT02017925 - Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation N/A
Recruiting NCT01829880 - Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure N/A
Completed NCT01692990 - Study on the Effect of Fish Oil and Appetite Phase 0
Completed NCT01419145 - A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study N/A
Completed NCT00994669 - Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients N/A
Completed NCT01015274 - Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients
Terminated NCT00962234 - Metabolism of Lipids in Advanced Cancer N/A
Terminated NCT00851448 - Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients N/A
Completed NCT00972634 - Computerized Questionnaires in Assessing Symptoms, Pain, Depression, and Physical Function in Patients With Metastatic and/or Advanced Locoregional Cancer N/A
Terminated NCT00535015 - Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer Phase 2
Terminated NCT00558558 - Haelan and Nutrition in Cancer Patients Phase 2